| GRI is a highly innovative start-up biotech company developing a unique approach to treating some of the most debilitating diseases of our time. We develop Natural Killer T cell targeted therapies for liver disease and autoimmune disorders. NKT cells share properties of both NK and T cells, are a functional link between the innate and adaptive immune responses, regulate the expression of key cytokines and are critical in modulating the immune response. Our lead programs include NKT I cell inhibitors and type NKT II cell modulators. |
 |